A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>
Kevin Chiem, Desarey Morales Vasquez, Jesus A. Silvas, Jun‐Gyu Park, Michael S. Piepenbrink, Julien Sourimant, Michelle J. Lin, Alexander L. Greninger, Richard K. Plemper, Jordi B. Torrelles, Mark R. Walter, Juan Carlos de la Torre, James Kobie, Chengjin Ye, Luis Martínez‐Sobrido
Abstract
Importantly, results obtained with these bifluorescent-based assays recapitulate those observed with individual viruses, demonstrating their feasibility to rapidly advance our understanding of vaccine efficacy and to identify broadly protective human NAbs for the therapeutic treatment of SARS-CoV-2.
Topics & Concepts
BiologyVirologyIn vivoVero cellAntibodyCoronavirusMonoclonal antibodyIn vitroNeutralizing antibodyVirusImmunologyCoronavirus disease 2019 (COVID-19)GeneticsInfectious disease (medical specialty)DiseaseMedicinePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing